



(51) International Patent Classification:

C12P 21/00 (2006.01) *A61P 11/00* (2006.01)
C07K 14/81 (2006.01) *A61P 1/16* (2006.01)
A61K 38/55 (2006.01)

(21) International Application Number:

PCT/SG2020/050154

(22) International Filing Date:

23 March 2020 (23.03.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10201902822V 29 March 2019 (29.03.2019) SG

(71) Applicants: **AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 1 Fusionopolis Way, #20-10, Connexis North Tower, Singapore 138632 (SG). **THE UNIVERSITY OF MANCHESTER** [GB/GB]; Oxford Road, Manchester M13 9PL (GB).

(72) Inventors: **CHOO, Sern Farh Matthew**; c/o Bioprocessing Technology Institute, 20 Biopolis Way, #06-01, Centros, Singapore 138668 (SG). **NGUYEN-KHUONG, Terry**; c/o Bioprocessing Technology Institute, 20 Biopolis Way, #06-01, Centros, Singapore 138668 (SG). **PAL-**

LISTER, Edward George; c/o Bioprocessing Technology Institute, 20 Biopolis Way, #06-01, Centros, Singapore 138668 (SG). **NG, Say Kong**; c/o Bioprocessing Technology Institute, 20 Biopolis Way, #06-01, Centros, Singapore 138668 (SG). **FLITSCH, Sabine Lahja**; do MW & School of Chemistry, University of Manchester, 131 Princess Street, Manchester M1 7DN (GB).

(74) Agent: **DAVIES COLLISON CAVE ASIA PTE. LTD.**; 10 Collyer Quay #07-01, Ocean Financial Centre, Singapore 049315 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: METHOD OF SIALYLATING A PROTEIN




FIGURE 1

(57) Abstract: The invention relates to a method of increasing the number of $\alpha 2,3$ - $\alpha 2,6$ -disialylgalactose *N*-glycans on a glycoprotein by incubating an $\alpha 2,3$ -sialylated glycoprotein with an $\alpha 2,6$ -sialyltransferase and a sialic acid source. Also provided is a recombinant glycoprotein comprising at least one $\alpha 2,3$ - $\alpha 2,6$ -disialylgalactose *N*-glycan. In a particular embodiment, the recombinant glycoprotein is alpha-1 antitrypsin (AAT).

[Continued on next page]

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*